| Literature DB >> 30596787 |
Xia Zhu1,2, Lujun Zhang1, Yangxi Hu1, Jianliang Zhang1.
Abstract
The imbalance in homocysteine (Hcy) metabolism has been implicated in the pathogenesis of human diseases, including cardiovascular and neurodegenerative disorders. When attempting to identify gene expression profiles using quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), the selection of suitable reference genes is important. Here, the expression levels of 10 commonly used reference genes were assessed for normalization of RT-qPCR in Hcy-treated human umbilical vein endothelial cells (HUVECs) and control cells. The suitability of eight selected candidate genes was comparatively analyzed across the tested samples and separately ranked by four programs, geNorm, NormFinder, BestKeeper, and the ΔCt method. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was the most stable gene in the final ranking using the RankAggreg package. Surprisingly, the β-actin (ACTB) levels decreased significantly in Hcy-treated HUVECs compared with control HUVECs (P<0.05), and further study indicated that Hcy suppressed the expression of ACTB by upregulating the miR-145-5p level in Hcy-treated HUVECs. Our data suggest that GAPDH can be used as a reliable reference gene, while ACTB cannot; normalization of gene expression in RT-qPCR experiments in Hcy-treated HUVECs. The data, which identifies a suitable reference gene in Hcy-treated HUVECs, will contribute to the design of an effective and accurate method for quantitation of gene expression.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30596787 PMCID: PMC6312244 DOI: 10.1371/journal.pone.0210087
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers for candidate reference genes.
| Symbol | Accession | Name | Primer Sequences (5'-3') | Am (bp) | |
|---|---|---|---|---|---|
| HPRT | NM_000194 | Hypoxanthine phosphoribosyl-transferase | F: | R: | 131 |
| Rpl13A | NM_012423 | Ribosomal protein L13A | F: | R: | 117 |
| 18s rRNA | NR_046235.1 | 18s subunit ribosomal RNA | F: | R: | 169 |
| U6 | NR_004394.1 | U6 small nuclear 1 | F: | R: | 94 |
| YWHAZ | NM_001135702 | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zetapolypeptide | F: | R: | 100 |
| PPIA | NM_021130 | peptidylprolyl isomerase A | F: | R: | 118 |
| GAPDH | NM_001256799 | Glyceraldehyde-3-phosphate dehydrogenase | F: | R: | 101 |
| ACTB | NM_001101.3 | Beta-actin | F: | R: | 137 |
| B2M | NM_004048 | Beta-2 microglobulin | F: | R: | 163 |
| TBP | NM_003194 | TATA box binding protein | F: | R: | 132 |
F: Forward primer; R: Reverse primer; Am: amplicon size; bp: numer of base pairs.
Ranking order of the candidate reference genes by four programs: geNorm, NormFinder, BestKeeper and ΔCt.
| Rank | geNorm | NormFinder | BestKeeper | ΔCt | ||||
|---|---|---|---|---|---|---|---|---|
| Gene | Stability (M) | Gene | variability | Gene | CV (%Ct) | Gene | Mean SD | |
| 1 | U6/TPB | 0.172 | GAPDH | 0.066 | GAPDH | 0.44 | GAPDH | 0.322 |
| 2 | U6 | 0.132 | TPB | 0.95 | B2M | 0.352 | ||
| 3 | GAPDH | 0.249 | TPB | 0.145 | U6 | 1.08 | U6 | 0.359 |
| 4 | B2M | 0.275 | B2M | 0.147 | B2M | 1.3 | TPB | 0.364 |
| 5 | Rpl13A | 0.291 | ppIA | 0.199 | ppIA | 1.59 | Rpl13 | 0.393 |
| 6 | ppIA | 0.312 | Rpl13A | 0.207 | Rpl13A | 1.61 | YWHAZ | 0.408 |
| 7 | YWHAZ | 0.357 | YWHAZ | 0.294 | YWHAZ | 1.74 | ppIA | 0.415 |
| 8 | 18s rRNA | 0.409 | 18s rRNA | 0.347 | 18s rRNA | 2.77 | 18s rRNA | 0.595 |
M: the mean expression stability values; CV: the coefficient of variance; Mean SD: mean standard deviation.
Fig 1Evaluation of reference genes using geNorm across all tested samples.
Determination of the optimal number of reference genes for normalization relied on the pairwise variation (Vn/n + 1) analysis. Every bar represents a change in normalization accuracy with the stepwise addition more of reference genes. The figure indicates that there is no need to include more than two genes into the normalization factor.
Final rankings of candidate reference genes.
| Rank | geNorm | NormFinder | BestKeeper | ΔCt | Final Fank |
|---|---|---|---|---|---|
| 1 | U6/TPB | GAPDH | GAPDH | GAPDH | GAPDH |
| 2 | U6 | TPB | B2M | U6 | |
| 3 | GAPDH | TPB | U6 | U6 | TBP |
| 4 | B2M | B2M | B2M | TPB | B2M |
| 5 | Rpl13A | ppIA | ppIA | Rpl13 | Rpl13A |
| 6 | ppIA | Rpl13A | Rpl13A | YWHAZ | ppIA |
| 7 | YWHAZ | YWHAZ | YWHAZ | ppIA | YWHAZ |
| 8 | 18s rRNA | 18s rRNA | 18s rRNA | 18s rRNA | 18s rRNA |
geNorm, NormFinder, BestKeeper and ΔCt method were combined to establish a consensus rank of the genes by RankAggreg package.
Fig 2Comparisons of mir-145-5p and ACTB levels in the five groups.
(A) Expressionof miR-145-5p were detected by RT-qPCR; (B-C) The mRNA and protein levels of ACTB was detected by RT-qPCR and western blot, respectively. * P<0.05 compared with control group; ** P<0.05 compared with miR-145 inhibitors group.
Primers for target miRNAs.
| Symbol | Accession | Primer Sequences (5'-3') | Am (bp) |
|---|---|---|---|
| miR-145-5p | MIMAT0000437 | RT: | 77 |
| F: | |||
| R: | |||
| miR-1-3p | MIMAT0000416 | RT: | 75 |
| F: | |||
| R: | |||
| miR-124-3p | MIMAT0000422 | RT: | 74 |
| F: | |||
| R: | |||
| miR-205-5p | MIMAT0000266 | RT: | 76 |
| F: | |||
| R: |
RT: retro-transcription primer; F: Forward primer; R: Reverse primer; Am: amplicon size; bp: numer of base pairs.
Fig 3qRT-PCR analysis of miR-1-3p, miR-124-3p, miR-145-5p and miR-205-5p in Hcy-treated HUVECs.
Only the miR-145-5p level increased significantly in the Hcy group compared with the control group. * P<0.05 when compared with control group.